BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yellepeddi VK, Joseph A, Nance E. Pharmacokinetics of nanotechnology-based formulations in pediatric populations. Adv Drug Deliv Rev 2019;151-152:44-55. [PMID: 31494124 DOI: 10.1016/j.addr.2019.08.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Alejo T, Uson L, Arruebo M. Reversible stimuli-responsive nanomaterials with on-off switching ability for biomedical applications. Journal of Controlled Release 2019;314:162-76. [DOI: 10.1016/j.jconrel.2019.10.036] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
2 Mabrouk M, Das DB, Salem ZA, Beherei HH. Nanomaterials for Biomedical Applications: Production, Characterisations, Recent Trends and Difficulties. Molecules 2021;26:1077. [PMID: 33670668 DOI: 10.3390/molecules26041077] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Patel JP, Spiller SE, Barker ED. Drug penetration in pediatric brain tumors: Challenges and opportunities. Pediatr Blood Cancer 2021;68:e28983. [PMID: 33719183 DOI: 10.1002/pbc.28983] [Reference Citation Analysis]
4 Zhang Z, Liu G, Ma R, Qi X, Wang G, Zhu B, Ling F. The immunoprotective effect of whole-cell lysed inactivated vaccine with SWCNT as a carrier against Aeromonas hydrophila infection in grass carp. Fish Shellfish Immunol 2020;97:336-43. [PMID: 31874296 DOI: 10.1016/j.fsi.2019.12.069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Khuroo T, Dharani S, Mohamed EM, Immadi S, Wu Z, Khan MA, Lu D, Nehete P, Rahman Z. Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations. Int J Pharm 2021;607:120889. [PMID: 34271151 DOI: 10.1016/j.ijpharm.2021.120889] [Reference Citation Analysis]
6 Deng Y, Shen L, Yang Y, Shen J. Development of nanoparticle-based orodispersible palatable pediatric formulations. Int J Pharm 2021;596:120206. [PMID: 33493595 DOI: 10.1016/j.ijpharm.2021.120206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tavares Luiz M, Santos Rosa Viegas J, Palma Abriata J, Viegas F, Testa Moura de Carvalho Vicentini F, Lopes Badra Bentley MV, Chorilli M, Maldonado Marchetti J, Tapia-Blácido DR. Design of experiments (DoE) to develop and to optimize nanoparticles as drug delivery systems. Eur J Pharm Biopharm 2021;165:127-48. [PMID: 33992754 DOI: 10.1016/j.ejpb.2021.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Nieto González N, Obinu A, Rassu G, Giunchedi P, Gavini E. Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics? Pharmaceutics 2021;13:670. [PMID: 34066953 DOI: 10.3390/pharmaceutics13050670] [Reference Citation Analysis]
9 Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in Oral Drug Delivery. Front Pharmacol 2021;12:618411. [PMID: 33679401 DOI: 10.3389/fphar.2021.618411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]